鼻窦恶性肿瘤治疗后全身18F-FDG PET/CT监测间隔的合适时机
回顾性分析80例鼻窦恶性肿瘤患者治疗后共197次全身18F-FDG PET/CT检查,按治疗后时间间隔分组,评估诊断复发的准确性及对生存的预后价值。结果显示1-3个月和>18个月组的阴性预测值和阳性预测值较高,PET/CT阳性发现是不良总生存的独立预测因素。结论认为全身18F-FDG PET/CT可识别治疗后复发,最佳扫描间隔为治疗后1-3个月和>18个月。
要点
- 治疗后1-3个月和>18个月行全身18F-FDG PET/CT监测复发,阴性预测值和阳性预测值均较高。
- PET/CT阳性发现是不良总生存的独立预测因素。
- 治疗后<1个月、3-6个月、6-12个月、12-18个月监测的预测值相对较低。
核心结论
- 全身18F-FDG PET/CT能够识别鼻窦恶性肿瘤治疗后的复发,最佳扫描间隔为治疗后1-3个月和>18个月。
- PET/CT阳性发现是不良总生存的独立预测因素(p < 0.05)。
研究设计与样本
- 回顾性研究,经机构审查委员会批准,纳入80例鼻窦恶性肿瘤患者,共197次治疗后全身18F-FDG PET/CT检查。
- 按治疗后时间间隔分为<1个月、1-3个月、3-6个月、6-12个月、12-18个月和>18个月组。
- 采用受试者工作特征曲线(ROC)计算不同随访间隔的诊断准确性差异,Cox比例风险模型评估监测性18F-FDG PET/CT的预后价值。
诊断标准与关键数值
- 预测总体复发的阴性预测值和阳性预测值:1-3个月组分别为100%和100%,>18个月组分别为100%和95%。
- 预测总体复发的阴性预测值和阳性预测值:<1个月组分别为50%和100%,3-6个月组分别为81%和93%,6-12个月组分别为79%和87%,12-18个月组分别为75%和80%。
- 1-3个月组和>18个月组的阴性预测值和阳性预测值高于其他时间间隔组(p < 0.05)。
临床应用与阅片要点
- 原文结论认为全身18F-FDG PET/CT可用于识别鼻窦恶性肿瘤治疗后复发,最佳扫描间隔为治疗后1-3个月和>18个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess the ideal timing of posttreatment whole-body 18F-FDG PET/CT examination as routine surveillance to determine local recurrence (R), lymph node metastasis (LM), and distant metastasis (DM) of sinonasal malignancies and to investigate the effect of 18F-FDG PET/CT on survival.
METHODS: An overall 80 patients who had undergone a total of 197 posttreatment whole-body 18F-FDG PET/CT examinations for sinonasal malignancy were retrospectively examined after institutional review board approval. Patients were grouped regarding the time intervals (<1 month, 1-3 months, 3-6 months, 6-12 months, 12-18 months and >18 months) after the conclusion of treatment. Differences in diagnostic accuracy due to different follow-up intervals were calculated by receiver operator curves (ROC) and a Cox proportional hazards model was used to assess the prognostic value of surveillance 18F-FDG PET/CT.
RESULTS: Considering the time intervals of posttreatment 18F-FDG PET/CT scans, the negative predictive value and positive predictive value of the 18F-FDG PET/CT examinations to predict overall recurrence in 1-3 months (100 and 100%, respectively) and >18 months (100 and 95%, respectively) were higher than for recurrence detection in <1 month (50 and 100%, respectively), 3-6 months (81 and 93%, respectively), 6-12 months (79 and 87%, respectively), and 12-18 months (75 and 80%, respectively) (p < 0.05). Positive findings on 18F-FDG PET/CT scans were also independent predictors of poorer overall survival (OS) (p < 0.05).
CONCLUSIONS: Whole-body 18F-FDG PET/CT is capable of identifying recurrences following treatment, using an optimal time interval for scanning of 1-3 months and >18 months after therapy.
引用
- Ozturk K, Gencturk M, Caicedo-Granados E, et al. Appropriate timing of surveillance intervals with whole-body 18F-FDG PET/CT following treatment for sinonasal malignancies. Eur J Radiol. 2019. PMID: 31439262. doi:10.1016/j.ejrad.2019.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。